These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32067628)

  • 1. Malaria Parasitemia and Nutritional Status during the Low Transmission Season in the Presence of Azithromycin Distribution among Preschool Children in Niger.
    Arzika AM; Maliki R; Boubacar N; Kane S; Cook CA; Lebas E; Lin Y; O'Brien KS; Austin A; Keenan JD; Lietman TM; Oldenburg CE; For The Mordor Study Group
    Am J Trop Med Hyg; 2020 Sep; 103(3):1315-1318. PubMed ID: 32067628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of mass azithromycin distribution on malaria parasitemia during the low-transmission season in Niger: a cluster-randomized trial.
    Gaynor BD; Amza A; Kadri B; Nassirou B; Lawan O; Maman L; Stoller NE; Yu SN; Chin SA; West SK; Bailey RL; Rosenthal PJ; Keenan JD; Porco TC; Lietman TM
    Am J Trop Med Hyg; 2014 May; 90(5):846-51. PubMed ID: 24615132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nutritional status in young children prior to the malaria transmission season in Burkina Faso and Mali, and its impact on the incidence of clinical malaria.
    de Wit M; Cairns M; Compaoré YD; Sagara I; Kuepfer I; Zongo I; Barry A; Diarra M; Tapily A; Coumare S; Thera I; Nikiema F; Yerbanga RS; Guissou RM; Tinto H; Dicko A; Chandramohan D; Greenwood B; Ouedraogo JB
    Malar J; 2021 Jun; 20(1):274. PubMed ID: 34158054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged mass azithromycin distributions and macrolide resistance determinants among preschool children in Niger: A sub-study of a cluster-randomized trial (MORDOR).
    Arzika AM; Abdou A; Maliki R; Beido N; Kadri B; Harouna AN; Galo AN; Alio MK; Lebas E; Oldenburg CE; O'Brien KS; Chen C; Zhong L; Zhou Z; Yan D; Hinterwirth A; Keenan JD; Porco TC; Lietman TM; Doan T;
    PLoS Med; 2024 May; 21(5):e1004386. PubMed ID: 38709718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass Azithromycin Distribution to Prevent Child Mortality in Burkina Faso: The CHAT Randomized Clinical Trial.
    Oldenburg CE; Ouattara M; Bountogo M; Boudo V; Ouedraogo T; Compaoré G; Dah C; Zakane A; Coulibaly B; Bagagnan C; Hu H; O'Brien KS; Nyatigo F; Keenan JD; Doan T; Porco TC; Arnold BF; Lebas E; Sié A; Lietman TM
    JAMA; 2024 Feb; 331(6):482-490. PubMed ID: 38349371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distance to Health Centers and Effectiveness of Azithromycin Mass Administration for Children in Niger: A Secondary Analysis of the MORDOR Cluster Randomized Trial.
    Chao DL; Arzika AM; Abdou A; Maliki R; Karamba A; Galo N; Beidi D; Harouna N; Abarchi M; Root E; Mishra A; Lebas E; Arnold BF; Oldenburg CE; Keenan JD; Lietman TM; O'Brien KS
    JAMA Netw Open; 2023 Dec; 6(12):e2346840. PubMed ID: 38100110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, randomized controlled comparison of three renutrition strategies for the management of moderate acute malnutrition among children aged from 6 to 24 months (the MALINEA project).
    Vray M; Hedible BG; Adam P; Tondeur L; Manirazika A; Randremanana R; Mainassara H; Briend A; Artaud C; von Platen C; Altmann M; Jambou R
    Trials; 2018 Dec; 19(1):666. PubMed ID: 30514364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical analysis plan for the LAKANA trial: a cluster-randomized, placebo-controlled, double-blinded, parallel group, three-arm clinical trial testing the effects of mass drug administration of azithromycin on mortality and other outcomes among 1-11-month-old infants in Mali.
    Luoma J; Adubra L; Alber D; Ashorn P; Ashorn U; Cloutman-Green E; Diallo F; Ducker C; Elovainio R; Fan YM; Gates L; Gruffudd G; Haapaniemi T; Haidara F; Hallamaa L; Ihamuotila R; Klein N; Martell O; Sow S; Vehmasto T; Cheung YB
    Trials; 2023 Nov; 24(1):733. PubMed ID: 37968741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azithromycin during Routine Well-Infant Visits to Prevent Death.
    Sié A; Ouattara M; Bountogo M; Boudo V; Ouedraogo T; Compaoré G; Dah C; Bagagnan C; Lebas E; Hu H; Rice J; Porco TC; Arnold BF; Lietman TM; Oldenburg CE
    N Engl J Med; 2024 Jan; 390(3):221-229. PubMed ID: 38231623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent malaria does not substantially impact COVID-19 antibody response or rates of symptomatic illness in communities with high malaria and COVID-19 transmission in Mali, West Africa.
    Woodford J; Sagara I; Diawara H; Assadou MH; Katile A; Attaher O; Issiaka D; Santara G; Soumbounou IH; Traore S; Traore M; Dicko OM; Niambele SM; Mahamar A; Kamate B; Haidara B; Sissoko K; Sankare S; Diarra SDK; Zeguime A; Doritchamou JYA; Zaidi I; Dicko A; Duffy PE
    Front Immunol; 2022; 13():959697. PubMed ID: 35990648
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gut microbiome alteration in MORDOR I: a community-randomized trial of mass azithromycin distribution.
    Doan T; Hinterwirth A; Worden L; Arzika AM; Maliki R; Abdou A; Kane S; Zhong L; Cummings ME; Sakar S; Chen C; Cook C; Lebas E; Chow ED; Nachamkin I; Porco TC; Keenan JD; Lietman TM
    Nat Med; 2019 Sep; 25(9):1370-1376. PubMed ID: 31406349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-arm clinical trial of improved flour targeting intestinal microbiota (MALINEA).
    Vray M; Tondeur L; Hedible BG; Randremanana RV; Manirakiza A; Lazoumar RH; Platen CV; Vargas A; Briend A; Jambou R;
    Matern Child Nutr; 2024 Jul; 20(3):e13649. PubMed ID: 38599819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of Coronavirus Burden With Mass Azithromycin Distribution.
    Doan T; Hinterwirth A; Arzika AM; Worden L; Chen C; Zhong L; Oldenburg CE; Keenan JD; Lietman TM
    Clin Infect Dis; 2020 Nov; 71(16):2282-2284. PubMed ID: 32426812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass Drug Administration of Azithromycin to Reduce Child Mortality: Only for High-Mortality Settings?
    Tickell KD; Deichsel EL; Walson JL
    Am J Trop Med Hyg; 2020 Sep; 103(3):1274-1275. PubMed ID: 30734698
    [No Abstract]   [Full Text] [Related]  

  • 15. Assessment of spillover of antimicrobial resistance to untreated children 7 to 12 years old after mass drug administration of azithromycin for child survival in Niger: a secondary analysis of the MORDOR cluster-randomized trial.
    Peterson B; Arzika AM; Amza A; Maliki R; Mankara Karamba A; Moussa M; Kemago M; Liu Z; Houpt E; Liu J; Pholwat S; Doan T; Porco T; Keenan JD; Lietman TM; O'Brien KS
    Clin Infect Dis; 2024 May; ():. PubMed ID: 38739754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unravelling the Potential Mortality Benefits of Mass Drug Administration With Azithromycin in Niger.
    Bhutta ZA
    JAMA Netw Open; 2023 Dec; 6(12):e2346811. PubMed ID: 38100114
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of Population-Based Census versus Birth History for the Estimation of Under-5 Mortality in Niger.
    Peterson B; Arzika AM; Amza A; Karamba A; Dodo NH; Galo N; Beidi A; Moustapha A; Lebas E; Cook C; Keenan JD; Lietman TM; O'Brien KS
    Am J Trop Med Hyg; 2023 Dec; 109(6):1380-1387. PubMed ID: 37903434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a prospect for mass drug administration of azithromycin to reduce child mortality in sub-Saharan Africa?
    Amouzou A
    BMJ Evid Based Med; 2019 Oct; 24(5):e7-e8. PubMed ID: 30606733
    [No Abstract]   [Full Text] [Related]  

  • 19. Priorities in reducing child mortality: Azithromycin and other interventions.
    Mabey D; Okomo U; Greenwood B
    PLoS Med; 2020 Sep; 17(9):e1003364. PubMed ID: 32931499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies to Account for Design Misspecifications in Randomized Controlled Trials.
    Ruppert AS; Mandrekar SJ
    NEJM Evid; 2022 Apr; 1(4):EVIDe2200012. PubMed ID: 38319209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.